Page 244 - 2021_09-Haematologica-web

Letters to the Editor
6. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of inte- grated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.
7. Whitman SP, Ruppert AS, Marcucci G, et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood. 2007;109(12):5164-5167.
8. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognos- tically unfavorable subset of AML. Leukemia. 2000;14(5):796-804.
9. Dorrance AM, Liu S, Yuan W, et al. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alter- ations. J Clin Invest. 2006;116(10):2707-2716.
10. Abedin SM, Boddy CS, Munshi HG. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. Onco Targets Ther. 2016;9:5943-5953.
11. Alqahtani A, Choucair K, Ashraf M, et al. Bromodomain and extra- terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019;5(3):FSO372.
12.Dawson MA, Gudgin EJ, Horton SJ, et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia. 2014;28(2):311-320.
13. Bill M, Pathmanathan A, Karunasiri M, et al. EGFL7 antagonizes
NOTCH signaling and represents a novel therapeutic target in acute
myeloid leukemia. Clin Cancer Res. 2020;26(3):669-678.
14. Zorko NA, Bernot KM, Whitman SP, et al. Mll partial tandem dupli- cation and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid
leukemias. Blood. 2012;120(5):1130-1136.
15. Bernot KM, Nemer JS, Santhanam R, et al. Eradicating acute myeloid
leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. Blood. 2013; 122(23):3778-3783.
16. Dorrance AM, Neviani P, Ferenchak GJ, et al. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia. 2015;29(11):2143-2153.
17. Papaioannou D, Shen C, Nicolet D, et al. Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2017;114(23):E4641-E4647.
18. Papaioannou D, Petri A, Dovey OM, et al. The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutat- ed acute myeloid leukemia. Nat Commun. 2019;10(1):5351.
19. Li H, Durbin R. Fast and accurate long-read alignment with Burrows- Wheeler transform. Bioinformatics. 2010;26(5):589-595.
20. Zhang Y, Liu T, Meyer CA, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9(9):R137.
2532
haematologica | 2021; 106(9)